Tranexamic Acid and Imaging Contrast Dye: What Every Woman Needs to Know

What Is Tranexamic Acid and Why Do So Many Women Take It?

Tranexamic acid (TXA) is a synthetic lysine derivative that blocks plasminogen from binding to fibrin, which slows clot breakdown and reduces bleeding. For women, this mechanism is directly useful across several conditions that are driven by disordered fibrinolysis or heavy menstrual blood loss.

FDA-approved Lysteda (oral TXA 650 mg) is one of the few non-hormonal prescription options for heavy menstrual bleeding (HMB), making it especially relevant for women who cannot or prefer not to use hormonal contraception. Off-label, clinicians also prescribe TXA for:

• Perimenopause-related flooding episodes, where estrogen fluctuation destabilizes endometrial vasculature
• PCOS-associated HMB, often in women who have irregular but very heavy cycles
• Post-surgical or post-procedure bleeding (hysteroscopy, myomectomy, IUD insertion)
• Topical formulations for melasma and hormonal hyperpigmentation, which disproportionately affect women of reproductive age

How Common Is Heavy Menstrual Bleeding?

Approximately 1 in 5 women of reproductive age experiences heavy menstrual bleeding, defined as blood loss exceeding 80 mL per cycle or bleeding that significantly disrupts daily life. The prevalence rises during perimenopause, when anovulatory cycles create prolonged unopposed estrogen exposure and endometrial instability.

Because TXA is so widely prescribed across life stages, questions about imaging are common. Women getting CT scans for pelvic pain, MRIs for fibroid mapping, or contrast-enhanced angiograms for vascular conditions often ask whether they need to stop TXA beforehand.

The Actual Tranexamic Acid and Contrast Dye Interaction: What the Evidence Shows

There is no direct pharmacokinetic drug-drug interaction between tranexamic acid and iodinated contrast media (used in CT, fluoroscopy, and angiography) or gadolinium-based contrast agents (used in MRI). The two drugs do not share metabolic pathways, protein-binding sites, or renal transporters in a way that would cause one to accumulate when the other is present.

Why the Question Still Matters

The interaction concern is pharmacodynamic, not pharmacokinetic. Both agents can, in separate and independent ways, increase thrombotic risk in susceptible women:

Tranexamic acid: Blocks fibrinolysis. In large trials such as WOMAN (World Maternal Antifibrinolytic Trial, Lancet 2017), TXA administered within 3 hours of postpartum hemorrhage reduced death from bleeding by 19% without increasing thromboembolic events overall. Still, the drug's mechanism means it theoretically reduces the body's ability to dissolve clots that do form.

Iodinated contrast agents: High-osmolality contrast media have historically been associated with altered blood viscosity. Current low-osmolality and iso-osmolality agents carry much lower risk, but the ACR Manual on Contrast Media notes that contrast can provoke venous thrombosis at injection sites and, rarely, systemic coagulation changes.

Who Faces Meaningful Combined Risk?

For the average healthy woman having a routine contrast-enhanced scan while taking short-course TXA for her period, the absolute additional thrombotic risk is very low. The population where clinicians should pause and individualize are women with:

• A personal or family history of deep vein thrombosis or pulmonary embolism
• Known thrombophilia (Factor V Leiden, antiphospholipid syndrome, prothrombin gene mutation), which ACOG Practice Bulletin 197 estimates affects 5-8% of the general population
• Active or recent malignancy
• Prolonged immobility before or after the scan
• Use of estrogen-containing contraceptives or menopausal hormone therapy alongside TXA

The FDA prescribing information for tranexamic acid tablets lists thromboembolic events as a risk and contraindicates use in women with active thromboembolic disease or a high risk of thrombosis.

What the Label and Guidelines Actually Say

Neither the TXA prescribing label nor the ACR contrast guidelines explicitly prohibit co-administration. The absence of a prohibition is not the same as a green light when a woman has additional thrombotic risk factors. Your radiologist's pre-procedure questionnaire exists precisely to surface this kind of combination.

A practical decision framework for women on TXA who need contrast imaging:

| Clinical scenario | Recommended action | |---|---| | Healthy woman, no thrombophilia, short-course TXA for HMB | Inform radiologist; proceed with standard precautions | | Woman on combined OCP or HRT plus TXA | Discuss with prescriber; hydration and mobility post-scan emphasized | | Known thrombophilia or prior DVT/PE | Cardiology or hematology review before elective contrast scan; consider timing TXA pause around scan | | Pregnancy (obstetric emergency requiring TXA + contrast) | Benefit-risk decided by the obstetric team in real time; refer to W4 section below | | Renal impairment (eGFR <30) | TXA dose-reduction needed independently of contrast; both nephrotoxic risk and TXA accumulation require nephrology input |

Tranexamic Acid Across Women's Life Stages

Reproductive Years: PCOS, Fibroids, and Endometriosis

Women with PCOS frequently experience HMB during anovulatory cycles. A 2011 Cochrane review of antifibrinolytics for HMB found TXA reduced menstrual blood loss by approximately 40% compared with placebo, and by 11% compared with NSAIDs, with no significant increase in thromboembolic events in the trial populations studied.

Women with fibroids undergoing MRI for fibroid mapping (often with gadolinium contrast) are among those most likely to be on TXA at the time of the scan. Tell your radiologist about TXA use; they can note it and ensure post-scan hydration and mobility instructions are given.

Perimenopause: Estrogen Fluctuation and Flooding

Perimenopausal women who experience flooding episodes may use TXA for a few days each cycle. This group is also more likely to need CT or MRI for evaluation of pelvic pathology, endometrial thickening, or adnexal masses. The Menopause Society (formerly NAMS) 2022 position statement on abnormal uterine bleeding acknowledges TXA as an effective non-hormonal option for perimenopausal HMB.

Perimenopausal women on systemic hormone therapy (HT) already carry a modestly elevated venous thromboembolism (VTE) risk with oral formulations. Adding TXA during a contrast-imaging procedure is a moment to reassess that cumulative risk profile with your clinician.

Post-Menopause

Post-menopausal women should not be experiencing bleeding that requires TXA. Any post-menopausal bleeding requires evaluation to rule out endometrial pathology before TXA is ever considered. ACOG Practice Bulletin 149 recommends endometrial sampling for all women with post-menopausal bleeding. TXA is not a first-line approach in this group.

Pregnancy and Lactation Safety: The Required Section

Pregnancy

Tranexamic acid crosses the placenta. A 2022 pharmacokinetic study published in BJOG confirmed fetal plasma concentrations reach approximately 30% of maternal concentrations after IV administration.

The drug is used in obstetric hemorrhage with strong evidence behind it. The WOMAN trial (Lancet 2017) enrolled 20,060 women with postpartum hemorrhage across 21 countries and showed that TXA given within 3 hours of delivery reduced death from bleeding by 19% (relative risk 0.81, 95% CI 0.65-1.00) and reduced laparotomy to control bleeding. This benefit-risk profile in life-threatening hemorrhage is clear.

Elective use during pregnancy is a different matter. TXA is not approved for use during the first trimester for non-emergency indications. Animal reproductive toxicology studies showed no teratogenicity, but human first-trimester data are sparse. The FDA label does not assign a traditional pregnancy category (the PLLR system replaced letter categories in 2015), but states that available data are insufficient to establish a drug-associated risk of major birth defects or miscarriage.

If you are trying to conceive: TXA taken in the luteal phase or early pregnancy should be discussed with your reproductive endocrinologist. There is no signal of harm, but the evidence base for elective first-trimester use is thin, and you deserve that transparency.

Contrast dye during pregnancy: Iodinated contrast is generally avoided in pregnancy unless the benefit clearly outweighs risk, given theoretical concerns about fetal thyroid suppression. Gadolinium contrast is classified by the ACR as a risk that should be weighed carefully. The combination of TXA plus contrast imaging in a pregnant woman should be a shared decision involving obstetrics and radiology, not a routine order.

Lactation

TXA transfers into breast milk in small amounts. A 1981 study by Kullander and Nilsson found breast-milk TXA concentrations were approximately 1% of the maternal serum concentration, translating to an infant relative dose well below the 10% threshold generally considered safe. The LactMed database (NIH) considers TXA compatible with breastfeeding, noting that the low oral bioavailability in infants further reduces systemic exposure.

If you are breastfeeding and need contrast imaging, gadolinium is considered compatible with continued breastfeeding by the ACR: the amount excreted into milk and absorbed by an infant is negligible.

Contraception Requirements

TXA is not a teratogen requiring mandatory contraception, unlike methotrexate or isotretinoin. Women of reproductive age taking TXA for HMB can use any contraceptive method, including non-hormonal options (copper IUD, barrier methods), which may also help with bleeding. Women who choose hormonal contraception alongside TXA should be aware of the additive VTE risk and discuss this with their clinician.

Can You Drink Alcohol While Taking Tranexamic Acid?

There is no pharmacokinetic interaction between TXA and alcohol. Alcohol does not inhibit TXA metabolism or increase its plasma concentration. The drug is renally excreted largely unchanged, and CYP450 enzymes are not significantly involved.

The practical concern is indirect. Heavy alcohol use can worsen underlying conditions that cause bleeding (such as alcohol-related liver disease reducing clotting factor production) and can increase gastrointestinal irritation. For women taking TXA specifically to manage heavy periods or postoperative bleeding, moderate alcohol intake is not contraindicated, but chronic heavy use may undermine the clinical goal.

Other Tranexamic Acid Drug Interactions Women Should Know

Hormonal Contraceptives and Hormone Therapy

The FDA label for TXA specifically notes that combined hormonal contraceptives (CHCs) are not recommended for concurrent use because both TXA and estrogen-containing contraceptives increase thrombotic risk. This warning reflects the pharmacodynamic additive risk, not a metabolic interaction.

Women on the combined pill who are prescribed TXA for breakthrough bleeding should have this combination reviewed by their prescriber. Progestogen-only methods (POP, hormonal IUD, implant, DMPA) do not carry the same VTE risk and are generally safe to combine with TXA.

Clotting Factors and Hemostatic Agents

Combining TXA with other pro-hemostatic agents (recombinant Factor VIIa, factor concentrates used in hemophilia A or B) theoretically increases thrombotic risk further. This combination is managed in specialist hematology settings.

Tretinoin (Topical) and TXA (Topical)

Women using topical TXA for melasma often also use topical retinoids. There is no systemic interaction. The combination is used intentionally in some dermatology protocols, with a 2020 study in the Journal of the American Academy of Dermatology showing topical TXA improved melasma scores as an adjunct to sun protection and other topical agents. The systemic absorption of topical TXA is minimal.

Who Is a Good Candidate for Tranexamic Acid, and Who Should Avoid It?

Right for TXA

• Women with confirmed HMB from fibroids, adenomyosis, PCOS, or idiopathic causes who prefer a non-hormonal approach
• Women in perimenopause experiencing flooding who cannot or prefer not to use hormonal therapy
• Women with PCOS who want short-course treatment on heavy cycle days without daily hormonal exposure
• Women undergoing uterine procedures (hysteroscopy, myomectomy) where prophylactic TXA reduces operative blood loss, per a 2019 meta-analysis in AJOG

Not Right for TXA

• Women with active thromboembolic disease (DVT, PE, cerebral sinus thrombosis)
• Women with subarachnoid hemorrhage (TXA is used for other hemostatic indications but not recommended here due to risk of cerebral vasospasm)
• Women with severe renal impairment unless dose-adjusted (TXA accumulates when eGFR falls <30 mL/min/1.73m²)
• Women with a history of seizures (IV TXA at high doses carries a dose-dependent seizure risk; oral doses at standard HMB dosing have a much lower signal, but caution applies)
• Post-menopausal women with unexplained bleeding before endometrial evaluation is complete

What to Tell Your Radiology Team Before a Contrast Scan

You deserve a scanner team that has your full picture. Before any contrast-enhanced imaging, tell the technologist and ordering clinician:

1. That you take TXA, including the dose and how many days per cycle.
2. Whether you also use combined hormonal contraceptives or systemic HT.
3. Any personal or family history of blood clots.
4. Whether you have a known thrombophilia.
5. Your current kidney function if you know it (contrast agents are cleared renally, and so is TXA).

This conversation takes under two minutes. It allows the radiologist to choose the lowest effective contrast dose, ensure you are well hydrated before and after, and document the combination in your record.

Renal Considerations: A Note on Both Drugs

TXA is renally eliminated with a half-life of approximately 2 hours; in women with chronic kidney disease, the drug accumulates and standard doses must be reduced. Iodinated contrast agents are also renally cleared and carry a risk of contrast-induced nephropathy in women with eGFR <30. Women who have both renal impairment and need for contrast imaging should have their TXA dosing reviewed simultaneously. These are separate considerations that happen to collide in the same kidney.

Evidence Gap: What We Do Not Yet Know for Women

Women have been under-represented in pharmacokinetic trials for TXA. Most dose-finding work was done in surgical populations that were predominantly male. The oral dose of 1,300 mg three times daily for HMB was studied in a predominantly female trial (the ULTRA trial and supporting studies for Lysteda), but the interaction data between TXA and contrast agents in women-specific populations (pregnant, perimenopausal, women on HT) comes from case series and extrapolation, not dedicated trials.

The thrombotic risk of TXA plus combined OCP plus contrast imaging in a perimenopausal woman with undiagnosed Factor V Leiden has not been studied directly. This is a gap. Until such data exist, individual risk stratification by your clinician is the right approach, not a blanket rule in either direction.